HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High
Key Points
The sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85.
The traded shares represent 13% of the equity stake held by the officer before the transaction.
The transaction involved directly held shares, with the executive retaining a direct ownership position of ~221,000 shares.
Vikram Verghese, Chief Financial Officer of HeartFlow, Inc. (NASDAQ:HTFL), sold 33,416 shares in trades executed on September 2, 2026 and September 3, 2026. SEC Form 4 filing
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $1.7 million |
| Shares sold (directly held) | 33,416 |
| Post-transaction shares (directly held) | 221,143 |
| Post-transaction value | $10.99 million |
Transaction value based on SEC Form 4 weighted average sale price ($49.85); post-transaction value based on September 3, 2026 market close ($49.71).
Key questions
- What prompted this disposition of common stock?
The trades were conducted according to a pre-arranged Rule 10b5-1 trading plan established on June 4, 2026, which allows corporate insiders to sell a predetermined number of shares at set times to avoid concerns regarding material non-public information. - What is the executive's remaining equity position in the company?
Following the disclosed sale, Vikram Verghese maintains a direct ownership interest of 221,143 shares, which represents an approximate 0.26% stake in the San Francisco-based medical technology company. - How has the stock performed relative to this liquidity event?
The company's stock returned 59% in the 12 months ending September 3, 2026, and was priced at $48.91 as of the September 4, 2026 market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-04) | $48.91 |
| Market Capitalization | $4.2 billion |
| Revenue (TTM) | $212.1 million |
| Net Income (TTM) | -$118.4 million |
Company Snapshot
- HeartFlow provides a proprietary artificial intelligence-powered platform that generates three-dimensional digital replicas of patients' hearts from coronary computed tomography angiography scans, enabling non-surgical diagnosis and management of coronary artery disease.
- The company generates revenue through licensing its HeartFlow Platform to healthcare providers and institutions, which utilize the technology to improve diagnostic accuracy and clinical decision-making for cardiac patients.
- HeartFlow's primary customers include hospitals, imaging centers, and cardiology practices globally that seek advanced diagnostic solutions to reduce unnecessary invasive procedures and improve patient outcomes in coronary artery disease management.
HeartFlow operates as a global medical technology company headquartered in San Francisco. The company has demonstrated significant market momentum, with its stock appreciating 58.92% over the past twelve months, reflecting investor confidence in its innovative cardiac diagnostic platform.
Despite current trailing 12-month net losses of $118.4 million, HeartFlow's competitive positioning in the high-growth cardiac imaging and artificial intelligence sectors positions it as a transformative player in non-invasive coronary artery disease diagnosis.
What this transaction means for investors
CFO Vikram Verghese's Sept. 2 and Sept. 3 sale of HeartFlow stock took place just as shares soared to a 52-week high of $51.78 on Sept. 2. The timing was fortuitous but coincidental, since his disposition was a non-discretionary transaction executed as part of a pre-established Rule 10b5-1 plan.
Post-sale, Verghese maintains a sizable direct equity stake exceeding 220,000. This ensures his continued alignment with shareholder interests.
HeartFlow stock is up because of its strong business performance. In the second quarter, sales reached $64.1 million. This represents an outstanding 48% year-over-year increase. Its gross margin rose to 83% compared to 75.5% in the previous year. The company also raised its 2026 full-year guidance.
On Aug. 28, HeartFlow announced independent clinical trial data revealed the company's medical technology reduces unnecessary invasive heart procedures by nearly half. This impressive validation of its tech also contributed to the share price increase.
Robert Izquierdo has positions in HeartFlow. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.